Literature DB >> 22229218

Veliparib plus temozolomide in metastatic melanoma trends toward increased PFS but results are not statistically significant.

.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 22229218

Source DB:  PubMed          Journal:  Oncology (Williston Park)        ISSN： 0890-9091            Impact factor:   2.990


× No keyword cloud information.
  2 in total

1.  A phase II evaluation of the potent, highly selective PARP inhibitor veliparib in the treatment of persistent or recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer in patients who carry a germline BRCA1 or BRCA2 mutation - An NRG Oncology/Gynecologic Oncology Group study.

Authors:  Robert L Coleman; Michael W Sill; Katherine Bell-McGuinn; Carol Aghajanian; Heidi J Gray; Krishnansu S Tewari; Steven C Rubin; Thomas J Rutherford; John K Chan; Alice Chen; Elizabeth M Swisher
Journal:  Gynecol Oncol       Date:  2015-03-24       Impact factor: 5.482

Review 2.  PARP Inhibitors for Recurrent Ovarian Carcinoma: Current Treatment Options and Future Perspectives.

Authors:  J Sehouli; E I Braicu; R Chekerov
Journal:  Geburtshilfe Frauenheilkd       Date:  2016-02       Impact factor: 2.915
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.